• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jexpmedHomeThe Rockefeller University PressThis articleEditorsContactInstructions for AuthorsThis issue
J Exp Med. Sep 26, 2011; 208(10): 1931–1935.
PMCID: PMC3182047

Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think

Abstract

Notch signaling is often considered a model hematopoietic proto-oncogene because of its role as the main trigger of T cell acute lymphoblastic leukemia (T-ALL). Although its role in T-ALL is well characterized and further supported by a high frequency of activating NOTCH1 mutations in T-ALL patients, it still remains an open question whether the effects of Notch signaling are causative in other types of cancer, including solid tumors. Growing evidence supported by recent studies unexpectedly shows that Notch signaling can also have a potent tumor suppressor function in both solid tumors and hematological malignancies. We discuss the intriguing possibility that the pleiotropic functions of Notch can be tumor suppressive or oncogenic depending on the cellular context.

Notch signaling is a highly evolutionarily conserved pathway implicated in diverse functions during embryogenesis and in self-renewing tissues of the adult organism. These functions include the maintenance of stem cells, cell fate specification, proliferation, and apoptosis (Artavanis-Tsakonas, 1988; Leong and Karsan, 2006). In mammals, there are four Notch receptors (Notch1-4), three Delta-like ligands (Dll1, Dll3, and Dll4), and two ligands of the Jagged family (Jag1 and Jag2). When membrane-bound receptors interact with cognate ligands on an adjacent cell, two consecutive proteolytic cleavages of the receptor are initiated, freeing the intracellular portion of Notch to enter the nucleus and activate the transcription of target genes. The first cleavage (S2) in the heterodimerization domain (HD) by ADAM10 (A disintegrin and metalloprotease 10) generates the substrate for the second cleavage (S3) by the γ-secretase complex. Canonical Notch signaling requires the formation of a complex with a transcription factor of the CSL (CBF-1/Su(H)/Lag-1) family, CBF-1/RBP-Jk/KBF2 in mammals. CBF-1 binds DNA in a sequence-specific manner and acts as a repressor of transcription in the absence of Notch signaling. Displacement of co-repressors bound to CBF-1 by intracellular Notch (ICN) allows the recruitment of co-activators, such as MamL1 (Mastermind Like-1), and histone acetyltransferases, such as p300, to create a short-lived transcriptional activation complex. Recent genome-wide chromatin immunoprecipitation arrays and sequencing have identified a large number of genes that can be regulated directly by Notch (Palomero et al., 2006; Hamidi et al., 2011). Many of these target genes may be cell type specific, but there are a few well characterized transcriptional targets of ICN-CBF1, including the HES (hairy enhancer of split) family of transcription factors, Notch-related ankryin repeat protein (NRARP), c-MYC, and DTX1 (Deltex1; Weng et al., 2006).

Notch as an oncogene

The first evidence for the involvement of Notch signaling in cancer came from T-ALL. T-ALL is a neoplastic disorder accounting for ~10–20% of all acute lymphoblastic leukemias. In 1991, Ellisen et al. (1991) identified a t(7;9)(q34;q34.4) translocation in T-ALL patients, which resulted in fusion of the 3′ region of NOTCH1 into the TCRβ locus and consequent overexpression of the active form of Notch1 (ICN1). This translocation appeared to be rare, found in <1% of T-ALL cases. However, 13 yr later, Weng et al. (2004) identified activating NOTCH1 mutations in ~56% of T-ALL cases examined, introducing NOTCH1 mutation as the main oncogenic lesion in T-ALL. Two major hotspots of mutations were characterized: mutations in the HD domain that induce ligand-independent activation, and mutations in the PEST (proline-glutamate-serine-threonine-rich) carboxy-terminal domain that increase stability of ICN1 (Thompson et al., 2007). Additionally, inactivating mutations were identified in FBW7, an E3 ubiquitin ligase responsible for ICN1 degradation and subsequent termination of Notch signaling (Malyukova et al., 2007; Maser et al., 2007; O’Neil et al., 2007; Thompson et al., 2007). Of note, animal modeling suggested that NOTCH1 mutations (HD or PEST) are either insufficient to induce disease or are very weak oncogenes in T-ALL, even when they are overexpressed (Chiang et al., 2008). We recently generated knockin mice carrying human NOTCH1 mutant alleles, and our studies also indicated that none of these mutations are sufficient to induce disease (unpublished data).

After the discovery of its involvement in T-ALL, Notch signaling was also implicated in various solid tumors, including breast cancer, medulloblastoma, colorectal cancer, non–small cell lung carcinoma (NSCLC), and melanoma (Ranganathan et al., 2011). The oncogenic potential of Notch activation in solid tumors was first observed in mouse mammary tumor virus (MMTV)–driven breast cancer. The integration of MMTV in specific loci of the host genome resulted in dysregulated expression of adjacent genes and subsequent outgrowth of tumorigenic clones. Characterization of one of these loci revealed expression of a truncated constitutively active form of Notch4 (Gallahan et al., 1987). In mouse models, Notch activation can clearly drive mammary tumors, and in human breast cancer, increased expression of Notch or Jag1 correlates with poor prognosis (Reedijk et al., 2005). However, few activating mutations of the Notch pathway have been found in solid tumor patients, with most being observed in NSCLC (Westhoff et al., 2009).

Two recent studies have identified activating NOTCH1 mutations in chronic lymphocytic leukemia (CLL), a frequent adult leukemia (Fabbri et al., 2011; Puente et al., 2011). CLL is characterized by variable clinical presentation and progression but can be divided into two major subtypes: one with mutated immunoglobulin genes (IGV(H)), and another more aggressive form with nonmutated IGV(H). Both studies identified NOTCH1-activating mutations (mainly a frame shift mutation at codon 2515) predicted to impair Fbw7-induced Notch1 degradation. Although the overall frequency was not dramatic (from 8.3 to 12.2%), these NOTCH1 mutations were primarily found in patients with the more clinically aggressive nonmutated IGV(H) subtype of CLL (20.4%) in Richter syndrome (31.0%), and in chemorefractory CLL (20.8%). These results suggest that although NOTCH1 mutations are not pathognomonic or causative of CLL, they are associated with poor prognosis and could define a distinct clinical subtype for therapeutic intervention.

Notch as a tumor suppressor

Although Notch activation (especially at higher levels as conferred by ICN1 expression) can be oncogenic, there is growing evidence that components of the same pathway may have growth-suppressive functions in other hematopoietic cells, skin, and pancreatic epithelium, as well as in hepatocytes.

In the skin, Notch receptor and ligand expression was found largely in the suprabasal cells, and in vitro data suggested that Notch activation induces differentiation and cell cycle arrest (Lowell et al., 2000; Rangarajan et al., 2001; Nguyen et al., 2006). Conditional deletion of NOTCH1 in the skin resulted in a significant increase of the basal epidermal layer (Rangarajan et al., 2001). Consistent with a tumor-suppressive function for Notch in the skin, NOTCH1 loss of function resulted in spontaneous basal cell carcinomas that appeared in older mice and sensitization to chemically induced skin carcinogenesis (Nicolas et al., 2003). This work also suggested that Notch acts as a tumor suppressor in the skin through suppression of the Wnt and Sonic–hedgehog pathways. A subsequent study indicated that the tumorigenic effect of Notch1 deletion is the result of a non–cell autonomous defect in the integrity of the skin barrier (Demehri and Kopan, 2009). Thus, mechanistically, tumor inhibition in the skin may involve feedback with the microenvironment in addition to cross talk between Notch and other signaling pathways.

In this issue of the Journal of Experimental Medicine, Viatour et al. (2011) propose a novel tumor suppressor role for Notch signaling in hepatocellular carcinoma (HCC). HCC is one of the most devastating cancers, with >600,000 deaths/yr worldwide, and is strongly associated with prior hepatitis virus B or C infection. To gain further insights into the mechanism driving initiation and progression of HCC, the authors generated a mouse model of the disease by deleting the retinoblastoma protein (RB) and its two related family members p107 and p130 in mouse liver. These triple KO (TKO) mice developed liver cancer with histological and molecular features typical of human HCC. In their model, inactivation of the RB pathway led to the expansion of the stem/progenitor compartment in the liver. The authors propose that these adult progenitor cells are the tumor-initiating cells of HCC after RB inactivation. In corroboration with previous findings showing that hyperactivation of E2F and Myc signals are sufficient to induce HCC, both pathways were up-regulated in the TKO mice.

Using whole transcriptome profiling and gene set enrichment analysis, Viatour et al. (2011) showed that the Notch pathway was also up-regulated in TKO mice, suggesting an oncogenic role for Notch signaling in HCC development. Unexpectedly, inhibition of Notch signaling in TKO mice using DAPT, a potent γ-secretase inhibitor, led to accelerated HCC development. And enforced activation of Notch signaling using ICN1 led to cell cycle arrest and apoptosis in primary HCC cells isolated from TKO mice, as well as in human HCC cell lines. To further address the clinical relevance of these observations, the authors looked at Notch activation status in a cohort of patients. They found that patients with better survival showed significantly higher expression of Notch-related genes, including HES1. Taken together, these data strongly support a potential tumor suppressor role for Notch signaling in HCC.

Our laboratory has recently found that conditional Notch loss-of-function through the deletion of Nicastrin (NCSTN), an essential component of the γ-secretase complex, or compound deletion of NOTCH1 and NOTCH2, resulted in a myeloproliferative syndrome with common features of the human disease chronic myelomonocytic leukemia (CMML; Klinakis et al., 2011). Whole transcriptome analysis revealed that Notch signaling inhibited a monocytic/granulocytic differentiation program in an early multipotential progenitor. This was at least partially mediated by direct repression of the PU.1 and C/EBPα promoters by HES1. Sequencing of Notch pathway genes revealed that ~12% of CMML patients harbored inactivating mutations in NCSTN, MAML1), APH1A, or NOTCH2. These mutations were unique to CMML and were not found in other myeloproliferative disorders such as Polycythemia vera and myelofibrosis. Analogous to the tumor-suppressive function of Notch in epithelial cells and HCC, these studies suggested that Notch signaling may also act to prevent uncontrolled proliferation and transformation of myeloid cells during hematopoietic development.

Furthermore, two recent studies of head and neck squamous cell carcinoma (HNSCC), the sixth most common cancer worldwide, identified mutations affecting Notch receptors. Agrawal et al. (2011) identified 28 different NOTCH1 mutations in 21/120 patients (17.5%). 11 of these mutations were nonsense or insertion/deletions predicted to result in loss of function, supporting a tumor-suppressive function for Notch in HNSCC. The remaining 17 were missense mutations, mostly within the extracellular EGF-like repeats that are required for receptor–ligand interaction. A study by Stransky et al. (2011) identified NOTCH1 mutations in 11% of patients analyzed and NOTCH2 or NOTCH3 mutations in an additional 11% of patients. Mutations identified in this study were nonsense, missense, or insertion/deletions targeting the extracellular domain of the Notch receptors and therefore predicted to be loss-of-function mutations. The significance of these mutations in HNSCC requires further validation; nevertheless, they implicate NOTCH1 as a tumor suppressor in HNSCC.

Finally, in B cell malignancies, Notch was also reported to suppress growth and induce apoptosis, providing additional evidence that Notch could act as a tumor suppressor in hematopoietic cells (Zweidler-McKay et al., 2005). Another recent study suggested a similar tumor suppressor role for Notch signaling in neuroblastoma (Zage et al., 2011). However these data were mostly generated from in vitro studies using enforced overexpression of ICN1 or stimulation with recombinant Notch ligand and will require further in vivo validation. It will thus be important to test the role of Notch in these disease models using in vivo genetic approaches.

Conclusion/future directions

Given that Notch is involved in an array of fundamental processes both during embryonic development and in adult tissues, it is perhaps not surprising that aberrant Notch signaling can result in a wide range of pathological consequences. The oncogenic function of Notch in lymphocytes and mammary tissue, versus the growth-suppressive role in HCC, CMML, HNSCC, and skin, highlights the intriguing dual role of a single signaling pathway (see Table I for a listing of Notch function in selected cancer types). Indeed, depending on the cellular context, Notch may promote stem cell maintenance or induce terminal differentiation.

Table I.
Dual role of Notch signaling in cancer

The detailed mechanistic explanation of this duality of action remains under investigation. We propose that in both cases (oncogenic and tumor suppressive function), Notch signaling mainly targets programs of stem and progenitor cell differentiation, acting as a cell fate determinant. By affecting normal differentiation, Notch could set the stage for additional mutations and eventual cell transformation. For example, in myeloid leukemia, defective Notch signaling (caused either by mutations or by gene silencing) commits stem cells and multipotential progenitors to the granulocytic/monocytic progenitor (GMP) fate, expanding the pool of putative leukemia-initiating cells (LICs). Additional oncogenic lesions, such as TET2 mutations (Moran-Crusio et al., 2011), could transform these cells and lead to the initiation of monocytic/granulocytic leukemia. On the flip side, Notch1-activating mutations direct progenitors toward the T cell lineage but are not sufficient for the induction of T-ALL in the absence of additional oncogenic lesions. Another possibility could be that Notch signaling is involved in terminal differentiation of multipotential progenitors, suppressing the accumulation of a potential cancer-initiating population. This latter mechanism could be involved in the induction of HCC, as Notch signaling seems to be activated in committed progenitors, defined by Viatour et al. (2011) as an HCC-initiating population, and not before their commitment.

Further detailed studies are required to integrate such hypotheses, including a detailed analysis of Notch receptor interactions with ligands in specialized tissue microenvironments. Moreover, with growing interest in clinical applications of γ-secretase inhibitors (GSIs) and blocking antibodies to Notch ligands, it is vital to understand all possible systemic consequences of Notch/RBP-J inhibition (Real et al., 2009). Whereas inhibition of Notch may have clinical efficacy where Notch has an oncogenic role, activation of Notch using peptides or antibodies should be evaluated as a therapeutic target in malignancies where NOTCH plays a tumor-suppressive role.

Acknowledgments

We would like to thank the members of the Aifantis laboratory for valuable discussions.

This work was supported by the National Institutes of Health (RO1CA133379, RO1CA105129, R21CA141399, RO1CA149655, and RO1GM088847 to I. Aifantis), the Leukemia & Lymphoma Society (TRP grant), the American Cancer Society (RSG0806801), the Irma T. Hirschl Trust, the Chemotherapy Foundation, and the V Foundation for Cancer Research. C. Lobry is supported by a fellowship by the Helen and Martin Kimmel Center for Stem Cell Biology at NYU. I. Aifantis is a Howard Hughes Medical Institute Early Career Scientist.

The authors declare no conflict of interest.

References

  • Agrawal N., Frederick M.J., Pickering C.R., Bettegowda C., Chang K., Li R.J., Fakhry C., Xie T.X., Zhang J., Wang J., et al. 2011. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 333:1154–1157.10.1126/science.1206923 [PMC free article] [PubMed] [Cross Ref]
  • Artavanis-Tsakonas S. 1988. The molecular biology of the Notch locus and the fine tuning of differentiation in Drosophila. Trends Genet. 4:95–100.10.1016/0168-9525(88)90096-0 [PubMed] [Cross Ref]
  • Chiang M.Y., Xu L., Shestova O., Histen G., L’heureux S., Romany C., Childs M.E., Gimotty P.A., Aster J.C., Pear W.S. 2008. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J. Clin. Invest. 118:3181–3194.10.1172/JCI35090 [PMC free article] [PubMed] [Cross Ref]
  • Demehri S., Kopan R. 2009. Notch signaling in bulge stem cells is not required for selection of hair follicle fate. Development. 136:891–896.10.1242/dev.030700 [PMC free article] [PubMed] [Cross Ref]
  • Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., Sklar J. 1991. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 66:649–661.10.1016/0092-8674(91)90111-B [PubMed] [Cross Ref]
  • Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., Grunn A., Fangazio M., Capello D., Monti S., et al. 2011. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J. Exp. Med. 208:1389–1401.10.1084/jem.20110921 [PMC free article] [PubMed] [Cross Ref]
  • Gallahan D., Kozak C., Callahan R. 1987. A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J. Virol. 61:218–220. [PMC free article] [PubMed]
  • Hamidi H., Gustafason D., Pellegrini M., Gasson J. 2011. Identification of novel targets of CSL-dependent Notch signaling in hematopoiesis. PLoS ONE. 6:e20022.10.1371/journal.pone.0020022 [PMC free article] [PubMed] [Cross Ref]
  • Hanlon L., Avila J.L., Demarest R.M., Troutman S., Allen M., Ratti F., Rustgi A.K., Stanger B.Z., Radtke F., Adsay V., et al. 2010. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 70:4280–4286.10.1158/0008-5472.CAN-09-4645 [PMC free article] [PubMed] [Cross Ref]
  • Klinakis A., Lobry C., Abdel-Wahab O., Oh P., Haeno H., Buonamici S., van De Walle I., Cathelin S., Trimarchi T., Araldi E., et al. 2011. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 473:230–233.10.1038/nature09999 [PMC free article] [PubMed] [Cross Ref]
  • Leong K.G., Karsan A. 2006. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 107:2223–2233.10.1182/blood-2005-08-3329 [PubMed] [Cross Ref]
  • Lowell S., Jones P., Le Roux I., Dunne J., Watt F.M. 2000. Stimulation of human epidermal differentiation by delta-notch signalling at the boundaries of stem-cell clusters. Curr. Biol. 10:491–500.10.1016/S0960-9822(00)00451-6 [PubMed] [Cross Ref]
  • Malyukova A., Dohda T., von der Lehr N., Akhoondi S., Corcoran M., Heyman M., Spruck C., Grandér D., Lendahl U., Sangfelt O. 2007. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res. 67:5611–5616.10.1158/0008-5472.CAN-06-4381 [PubMed] [Cross Ref]
  • Maser R.S., Choudhury B., Campbell P.J., Feng B., Wong K.-K., Protopopov A., O’Neil J., Gutierrez A., Ivanova E., Perna I., et al. 2007. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 447:966–971.10.1038/nature05886 [PMC free article] [PubMed] [Cross Ref]
  • Mazur P.K., Einwächter H., Lee M., Sipos B., Nakhai H., Rad R., Zimber-Strobl U., Strobl L.J., Radtke F., Klöppel G., et al. 2010. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl. Acad. Sci. USA. 107:13438–13443.10.1073/pnas.1002423107 [PMC free article] [PubMed] [Cross Ref]
  • Moran-Crusio K., Reavie L., Shih A., Abdel-Wahab O., Ndiaye-Lobry D., Lobry C., Figueroa M.E., Vasanthakumar A., Patel J., Zhao X., et al. 2011. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 20:11–24.10.1016/j.ccr.2011.06.001 [PMC free article] [PubMed] [Cross Ref]
  • Nguyen B.C., Lefort K., Mandinova A., Antonini D., Devgan V., Della Gatta G., Koster M.I., Zhang Z., Wang J., Tommasi di Vignano A., et al. 2006. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 20:1028–1042.10.1101/gad.1406006 [PMC free article] [PubMed] [Cross Ref]
  • Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., Hui C.C., Clevers H., Dotto G.P., Radtke F. 2003. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33:416–421.10.1038/ng1099 [PubMed] [Cross Ref]
  • O’Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., Hardwick J., Welcker M., Meijerink J.P., Pieters R., et al. 2007. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors. J. Exp. Med. 204:1813–1824.10.1084/jem.20070876 [PMC free article] [PubMed] [Cross Ref]
  • Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., Barnes K.C., O’Neil J., Neuberg D., Weng A.P., et al. 2006. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA. 103:18261–18266.10.1073/pnas.0606108103 [PMC free article] [PubMed] [Cross Ref]
  • Puente X.S., Pinyol M., Quesada V., Conde L., Ordóñez G.R., Villamor N., Escaramis G., Jares P., Beà S., González-Díaz M., et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 475:101–105.10.1038/nature10113 [PMC free article] [PubMed] [Cross Ref]
  • Ranganathan P., Weaver K.L., Capobianco A.J. 2011. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer. 11:338–351.10.1038/nrc3035 [PubMed] [Cross Ref]
  • Rangarajan A., Talora C., Okuyama R., Nicolas M., Mammucari C., Oh H., Aster J.C., Krishna S., Metzger D., Chambon P., et al. 2001. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 20:3427–3436.10.1093/emboj/20.13.3427 [PMC free article] [PubMed] [Cross Ref]
  • Real P.J., Tosello V., Palomero T., Castillo M., Hernando E., de Stanchina E., Sulis M.L., Barnes K., Sawai C., Homminga I., et al. 2009. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med. 15:50–58.10.1038/nm.1900 [PMC free article] [PubMed] [Cross Ref]
  • Reedijk M., Odorcic S., Chang L., Zhang H., Miller N., McCready D.R., Lockwood G., Egan S.E. 2005. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 65:8530–8537.10.1158/0008-5472.CAN-05-1069 [PubMed] [Cross Ref]
  • Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., Kryukov G.V., Lawrence M.S., Sougnez C., McKenna A., et al. 2011. The mutational landscape of head and neck squamous cell carcinoma. Science. 333:1157–1160.10.1126/science.1208130 [PMC free article] [PubMed] [Cross Ref]
  • Thompson B.J., Buonamici S., Sulis M.L., Palomero T., Vilimas T., Basso G., Ferrando A., Aifantis I. 2007. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204:1825–1835.10.1084/jem.20070872 [PMC free article] [PubMed] [Cross Ref]
  • Viatour P., Ehmer U., Saddic L.A., Dorrell C., Andersen J.B., Lin C., Zmoos A.F., Mazur P.K., Schaffer B.E., Ostermeier A., et al. 2011. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J. Exp. Med. 208:1963–1976. [PMC free article] [PubMed]
  • Weng A.P., Ferrando A.A., Lee W., Morris J.P., IV, Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 306:269–271.10.1126/science.1102160 [PubMed] [Cross Ref]
  • Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., Del Bianco C., Rodriguez C.G., Sai H., Tobias J., et al. 2006. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 20:2096–2109.10.1101/gad.1450406 [PMC free article] [PubMed] [Cross Ref]
  • Westhoff B., Colaluca I.N., D’Ario G., Donzelli M., Tosoni D., Volorio S., Pelosi G., Spaggiari L., Mazzarol G., Viale G., et al. 2009. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA. 106:22293–22298.10.1073/pnas.0907781106 [PMC free article] [PubMed] [Cross Ref]
  • Zage P.E., Nolo R., Fang W., Stewart J., Garcia-Manero G., Zweidler-McKay P.A. 2011. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr. Blood Cancer. [PMC free article] [PubMed]
  • Zweidler-McKay P.A., He Y., Xu L., Rodriguez C.G., Karnell F.G., Carpenter A.C., Aster J.C., Allman D., Pear W.S. 2005. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood. 106:3898–3906.10.1182/blood-2005-01-0355 [PMC free article] [PubMed] [Cross Ref]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...